WO2003004692A3 - Screening processes for agents modulating cholesterol levels - Google Patents

Screening processes for agents modulating cholesterol levels Download PDF

Info

Publication number
WO2003004692A3
WO2003004692A3 PCT/CA2002/001001 CA0201001W WO03004692A3 WO 2003004692 A3 WO2003004692 A3 WO 2003004692A3 CA 0201001 W CA0201001 W CA 0201001W WO 03004692 A3 WO03004692 A3 WO 03004692A3
Authority
WO
WIPO (PCT)
Prior art keywords
abca1
activity
protein
cholesterol levels
phosphatases
Prior art date
Application number
PCT/CA2002/001001
Other languages
French (fr)
Other versions
WO2003004692A2 (en
Inventor
Raymond See
Michael R Hayden
Original Assignee
Xenon Genetics Inc
Univ British Columbia
Raymond See
Michael R Hayden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Genetics Inc, Univ British Columbia, Raymond See, Michael R Hayden filed Critical Xenon Genetics Inc
Priority to AU2002317093A priority Critical patent/AU2002317093A1/en
Publication of WO2003004692A2 publication Critical patent/WO2003004692A2/en
Publication of WO2003004692A3 publication Critical patent/WO2003004692A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Methods for identifying agents that modulate the extent of phosphorylation of the protein product of the ABC1 gene through increase in the activity of ABCA1 phosphorylating enzymes, especially protein kinases, including protein kinase A (PKA) and protein kinase C (PKC) or by decreasing the activity of ABCA1 dephosphorylases, or phosphatases, especially Protein Phosphatase 1 (PP1) are disclosed. These processes include both in vitro and cell based assays. Also disclosed are processes for preventing diseases linked to the activity of ABCA1 activity by administering to a patient at risk of such diseases an amount of an agent that inhibits ABCA1 phosphatases or increases the activity of ABCA1 kinases.
PCT/CA2002/001001 2001-07-03 2002-07-03 Screening processes for agents modulating cholesterol levels WO2003004692A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002317093A AU2002317093A1 (en) 2001-07-03 2002-07-03 Screening processes for agents modulating cholesterol levels

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30285401P 2001-07-03 2001-07-03
US60/302,854 2001-07-03
CA0201085 2002-07-02
CAPCT/CA02/01085 2002-07-02

Publications (2)

Publication Number Publication Date
WO2003004692A2 WO2003004692A2 (en) 2003-01-16
WO2003004692A3 true WO2003004692A3 (en) 2003-09-18

Family

ID=25673742

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/001001 WO2003004692A2 (en) 2001-07-03 2002-07-03 Screening processes for agents modulating cholesterol levels

Country Status (2)

Country Link
AU (1) AU2002317093A1 (en)
WO (1) WO2003004692A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002304931A1 (en) * 2001-06-08 2002-12-23 University Of British Columbia Methods for treating disorders of the nervous and reproductive systems
WO2009007080A1 (en) * 2007-07-06 2009-01-15 University Of Zurich Method of preventing and treating acute brain pathologies
KR102077333B1 (en) * 2016-10-24 2020-02-13 (주)벳바젠 Compositions comprising protein phosphatase 1(PP1) inhibitory peptides for treating vascular diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055318A2 (en) * 1999-03-15 2000-09-21 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
WO2000078971A2 (en) * 1999-06-18 2000-12-28 Cv Therapeutics, Inc. Atp binding cassette transporter protein abc1 popypeptides
WO2001062954A2 (en) * 2000-02-24 2001-08-30 Xenon Genetics, Inc. Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
EP1130400A1 (en) * 2000-02-08 2001-09-05 Pfizer Products Inc. Assay for ABCA1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055318A2 (en) * 1999-03-15 2000-09-21 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
WO2000078971A2 (en) * 1999-06-18 2000-12-28 Cv Therapeutics, Inc. Atp binding cassette transporter protein abc1 popypeptides
EP1130400A1 (en) * 2000-02-08 2001-09-05 Pfizer Products Inc. Assay for ABCA1
WO2001062954A2 (en) * 2000-02-24 2001-08-30 Xenon Genetics, Inc. Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents

Also Published As

Publication number Publication date
AU2002317093A1 (en) 2003-01-21
WO2003004692A2 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
Abou-Donia Organophosphorus ester-induced chronic neurotoxicity
Morley et al. Differential stimulation of phosphorylation of initiation factors eIF-4F, eIF-4B, eIF-3, and ribosomal protein S6 by insulin and phorbol esters.
Jozwiak Hamartin and tuberin: working together for tumour suppression
WO2001094312A3 (en) Indolinone derivatives as protein kinase/phosphatase inhibitors
WO2002002190A3 (en) Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
Johansen et al. Phosphorylation and inactivation of protein phosphatase 1 by pp60v-src.
Testai et al. Acid sphingomyelinase and inhibition by phosphate ion: role of inhibition by phosphatidyl‐myo‐inositol 3, 4, 5‐triphosphate in oligodendrocyte cell signaling
CA2253348A1 (en) Regulating metabolism by modifying the level of trehalose-6-phosphate
BR9810955A (en) "4-5-diaryl 2-substituted imidazoles"
BG100911A (en) Biophosphonic acids-sontaining wet-granulated form
She et al. Growth factor‐like effects of placental alkaline phosphatase in human fetus and mouse embryo fibroblasts
AU3743499A (en) Phosphinic acid derivatives
Willaime-Morawek et al. IGF-I protects cortical neurons against ceramide-induced apoptosis via activation of the PI-3K/Akt and ERK pathways; is this protection independent of CREB and Bcl-2?
WO2003004692A3 (en) Screening processes for agents modulating cholesterol levels
Williams Pharmacogenetics in model systems: defining a common mechanism of action for mood stabilisers
Beemer et al. Characterization of some glycolytic enzymes from human retina and retinoblastoma
WO2001070993A3 (en) Polynucleotides that control delta-6-desaturase genes and methods for identifying compounds for modulating delta-6-desaturase
WO2002029091A3 (en) Methods and compositions for the treatment of inflammatory diseases
Nimnual et al. Identification of phosphorylation sites on AChR δ-subunit associated with dispersal of AChR clusters on the surface of muscle cells
Schlender et al. Dephosphorylation of cardiac myofibril C-protein by protein phosphatase 1 and protein phosphatase 2A
Brady et al. Polyenylphosphatidylcholine inhibits PDGF-induced proliferation in rat hepatic stellate cells
WO1998049317A3 (en) Diagnosis and treatment of phosphatase- 0r kinase-related disorders
Jett et al. Noncholinesterase mechanisms of central and peripheral neurotoxicity: Muscarinic receptors and other targets
Salomo et al. How myeloma cells escape bisphosphonate‐mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics
WO2000000182A3 (en) Medicaments containing bisphosphonic acids and derivatives thereof which are provided for preventing and treating autoimmune diseases and allergies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP